Aligos Therapeutics, Inc. focuses on developing therapies for liver and viral diseases, particularly chronic hepatitis B virus (HBV) infection. The company utilizes its expertise in medicinal chemistry and biology to create a differentiated pipeline of treatments, including an oral small molecule capsid assembly modulator and a next-generation antisense oligonucleotide. Aligos targets unmet medical needs in hepatology and virology, aiming to improve patient outcomes through enhanced pharmacologic properties of its drug candidates.
